Systemic biomarkers of neutrophilic inflammation, tissue injury and repair in COPD patients with differing levels of disease severity.
The identification and validation of biomarkers to support the assessment of novel therapeutics for COPD continues to be an important area of research. The aim of the current study was to identify systemic protein biomarkers correlated with measures of COPD severity, as well as specific protein sign...
Guardado en:
| Autores principales: | , , , , , , , , , , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Public Library of Science (PLoS)
2012
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/d670836d162341129c02f54fff4b294d |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:d670836d162341129c02f54fff4b294d |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:d670836d162341129c02f54fff4b294d2021-11-18T07:15:45ZSystemic biomarkers of neutrophilic inflammation, tissue injury and repair in COPD patients with differing levels of disease severity.1932-620310.1371/journal.pone.0038629https://doaj.org/article/d670836d162341129c02f54fff4b294d2012-01-01T00:00:00Zhttps://www.ncbi.nlm.nih.gov/pmc/articles/pmid/22701684/?tool=EBIhttps://doaj.org/toc/1932-6203The identification and validation of biomarkers to support the assessment of novel therapeutics for COPD continues to be an important area of research. The aim of the current study was to identify systemic protein biomarkers correlated with measures of COPD severity, as well as specific protein signatures associated with comorbidities such as metabolic syndrome. 142 protein analytes were measured in serum of 140 patients with stable COPD, 15 smokers without COPD and 30 non-smoking controls. Seven analytes (sRAGE, EN-RAGE, NGAL, Fibrinogen, MPO, TGF-α and HB-EGF) showed significant differences between severe/very severe COPD, mild/moderate COPD, smoking and non-smoking control groups. Within the COPD subjects, univariate and multivariate analyses identified analytes significantly associated with FEV(1), FEV(1)/FVC and DLCO. Most notably, a set of 5 analytes (HB-EGF, Fibrinogen, MCP-4, sRAGE and Sortilin) predicted 21% of the variability in DLCO values. To determine common functions/pathways, analytes were clustered in a correlation network by similarity of expression profile. While analytes related to neutrophil function (EN-RAGE, NGAL, MPO) grouped together to form a cluster associated with FEV(1) related parameters, analytes related to the EGFR pathway (HB-EGF, TGF-α) formed another cluster associated with both DLCO and FEV(1) related parameters. Associations of Fibrinogen with DLCO and MPO with FEV(1)/FVC were stronger in patients without metabolic syndrome (r = -0.52, p = 0.005 and r = -0.61, p = 0.023, respectively) compared to patients with coexisting metabolic syndrome (r = -0.25, p = 0.47 and r = -0.15, p = 0.96, respectively), and may be driving overall associations in the general cohort. In summary, our study has identified known and novel serum protein biomarkers and has demonstrated specific associations with COPD disease severity, FEV(1), FEV(1)/FVC and DLCO. These data highlight systemic inflammatory pathways, neutrophil activation and epithelial tissue injury/repair processes as key pathways associated with COPD.Debra A CockayneDonavan T ChengBenjamin WaschkiSriram SridharPalanikumar RavindranHolly HiltonGalina KourtevaHans BitterSreekumar G PillaiSudha VisvanathanKai-Christian MüllerOlaf HolzHelgo MagnussenHenrik WatzJay S FinePublic Library of Science (PLoS)articleMedicineRScienceQENPLoS ONE, Vol 7, Iss 6, p e38629 (2012) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
Medicine R Science Q |
| spellingShingle |
Medicine R Science Q Debra A Cockayne Donavan T Cheng Benjamin Waschki Sriram Sridhar Palanikumar Ravindran Holly Hilton Galina Kourteva Hans Bitter Sreekumar G Pillai Sudha Visvanathan Kai-Christian Müller Olaf Holz Helgo Magnussen Henrik Watz Jay S Fine Systemic biomarkers of neutrophilic inflammation, tissue injury and repair in COPD patients with differing levels of disease severity. |
| description |
The identification and validation of biomarkers to support the assessment of novel therapeutics for COPD continues to be an important area of research. The aim of the current study was to identify systemic protein biomarkers correlated with measures of COPD severity, as well as specific protein signatures associated with comorbidities such as metabolic syndrome. 142 protein analytes were measured in serum of 140 patients with stable COPD, 15 smokers without COPD and 30 non-smoking controls. Seven analytes (sRAGE, EN-RAGE, NGAL, Fibrinogen, MPO, TGF-α and HB-EGF) showed significant differences between severe/very severe COPD, mild/moderate COPD, smoking and non-smoking control groups. Within the COPD subjects, univariate and multivariate analyses identified analytes significantly associated with FEV(1), FEV(1)/FVC and DLCO. Most notably, a set of 5 analytes (HB-EGF, Fibrinogen, MCP-4, sRAGE and Sortilin) predicted 21% of the variability in DLCO values. To determine common functions/pathways, analytes were clustered in a correlation network by similarity of expression profile. While analytes related to neutrophil function (EN-RAGE, NGAL, MPO) grouped together to form a cluster associated with FEV(1) related parameters, analytes related to the EGFR pathway (HB-EGF, TGF-α) formed another cluster associated with both DLCO and FEV(1) related parameters. Associations of Fibrinogen with DLCO and MPO with FEV(1)/FVC were stronger in patients without metabolic syndrome (r = -0.52, p = 0.005 and r = -0.61, p = 0.023, respectively) compared to patients with coexisting metabolic syndrome (r = -0.25, p = 0.47 and r = -0.15, p = 0.96, respectively), and may be driving overall associations in the general cohort. In summary, our study has identified known and novel serum protein biomarkers and has demonstrated specific associations with COPD disease severity, FEV(1), FEV(1)/FVC and DLCO. These data highlight systemic inflammatory pathways, neutrophil activation and epithelial tissue injury/repair processes as key pathways associated with COPD. |
| format |
article |
| author |
Debra A Cockayne Donavan T Cheng Benjamin Waschki Sriram Sridhar Palanikumar Ravindran Holly Hilton Galina Kourteva Hans Bitter Sreekumar G Pillai Sudha Visvanathan Kai-Christian Müller Olaf Holz Helgo Magnussen Henrik Watz Jay S Fine |
| author_facet |
Debra A Cockayne Donavan T Cheng Benjamin Waschki Sriram Sridhar Palanikumar Ravindran Holly Hilton Galina Kourteva Hans Bitter Sreekumar G Pillai Sudha Visvanathan Kai-Christian Müller Olaf Holz Helgo Magnussen Henrik Watz Jay S Fine |
| author_sort |
Debra A Cockayne |
| title |
Systemic biomarkers of neutrophilic inflammation, tissue injury and repair in COPD patients with differing levels of disease severity. |
| title_short |
Systemic biomarkers of neutrophilic inflammation, tissue injury and repair in COPD patients with differing levels of disease severity. |
| title_full |
Systemic biomarkers of neutrophilic inflammation, tissue injury and repair in COPD patients with differing levels of disease severity. |
| title_fullStr |
Systemic biomarkers of neutrophilic inflammation, tissue injury and repair in COPD patients with differing levels of disease severity. |
| title_full_unstemmed |
Systemic biomarkers of neutrophilic inflammation, tissue injury and repair in COPD patients with differing levels of disease severity. |
| title_sort |
systemic biomarkers of neutrophilic inflammation, tissue injury and repair in copd patients with differing levels of disease severity. |
| publisher |
Public Library of Science (PLoS) |
| publishDate |
2012 |
| url |
https://doaj.org/article/d670836d162341129c02f54fff4b294d |
| work_keys_str_mv |
AT debraacockayne systemicbiomarkersofneutrophilicinflammationtissueinjuryandrepairincopdpatientswithdifferinglevelsofdiseaseseverity AT donavantcheng systemicbiomarkersofneutrophilicinflammationtissueinjuryandrepairincopdpatientswithdifferinglevelsofdiseaseseverity AT benjaminwaschki systemicbiomarkersofneutrophilicinflammationtissueinjuryandrepairincopdpatientswithdifferinglevelsofdiseaseseverity AT sriramsridhar systemicbiomarkersofneutrophilicinflammationtissueinjuryandrepairincopdpatientswithdifferinglevelsofdiseaseseverity AT palanikumarravindran systemicbiomarkersofneutrophilicinflammationtissueinjuryandrepairincopdpatientswithdifferinglevelsofdiseaseseverity AT hollyhilton systemicbiomarkersofneutrophilicinflammationtissueinjuryandrepairincopdpatientswithdifferinglevelsofdiseaseseverity AT galinakourteva systemicbiomarkersofneutrophilicinflammationtissueinjuryandrepairincopdpatientswithdifferinglevelsofdiseaseseverity AT hansbitter systemicbiomarkersofneutrophilicinflammationtissueinjuryandrepairincopdpatientswithdifferinglevelsofdiseaseseverity AT sreekumargpillai systemicbiomarkersofneutrophilicinflammationtissueinjuryandrepairincopdpatientswithdifferinglevelsofdiseaseseverity AT sudhavisvanathan systemicbiomarkersofneutrophilicinflammationtissueinjuryandrepairincopdpatientswithdifferinglevelsofdiseaseseverity AT kaichristianmuller systemicbiomarkersofneutrophilicinflammationtissueinjuryandrepairincopdpatientswithdifferinglevelsofdiseaseseverity AT olafholz systemicbiomarkersofneutrophilicinflammationtissueinjuryandrepairincopdpatientswithdifferinglevelsofdiseaseseverity AT helgomagnussen systemicbiomarkersofneutrophilicinflammationtissueinjuryandrepairincopdpatientswithdifferinglevelsofdiseaseseverity AT henrikwatz systemicbiomarkersofneutrophilicinflammationtissueinjuryandrepairincopdpatientswithdifferinglevelsofdiseaseseverity AT jaysfine systemicbiomarkersofneutrophilicinflammationtissueinjuryandrepairincopdpatientswithdifferinglevelsofdiseaseseverity |
| _version_ |
1718423760626778112 |